Abstract Mutant isocitrate dehydrogenase 1 (mIDH1) inhibitors have shown single-agent
activity in relapsed/refractory acute myeloid leukemia (AML), even though most patients …

Acute myeloid leukemia is mainly characterized by a complex and dynamic genomic
instability. Next-generation sequencing has significantly improved the ability of diagnostic …

Therapeutic developments targeting acute myeloid leukemia (AML) have been in the
pipeline for five decades and have recently resulted in the approval of multiple targeted …

A differentiation block and an accumulation of immature myeloid cells characterize acute
myelogenous leukemia (AML). However, native AML cells usually show some …

For decades, intensive chemotherapy (IC) has been considered the best therapeutic option
for treating acute myeloid leukemia (AML), with no curative option available for patients who …

Cure rates for patients with acute myeloid leukemia (AML) remain low despite ever-
increasing dose intensity of cytotoxic therapy. In an effort to identify novel approaches to …

The heterogeneity of acute myeloid leukemia (AML) results from a complex network of
cytogenetic aberrations and molecular mutations. These genetic markers are the basis for …

Epigenetic regulators are recurrently mutated and aberrantly expressed in acute myeloid
leukemia (AML). Targeted therapies designed to inhibit these chromatin-modifying enzymes …

In the past few years, research in the underlying pathogenic mechanisms of acute myeloid
leukaemia (AML) has led to remarkable advances in our understanding of the disease …

Human myeloid leukemias provide models of maturation arrest and differentiation therapy of
cancer. The genetic lesions of leukemia result in a block of differentiation (maturation arrest) …